Vital Therapies reported $95.71M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Biomarin Pharmaceutical BMRN:US $ 605.44M 18.16M
Dynavax Technologies DVAX:US $ 179.42M 256.77M
Enanta Pharmaceuticals ENTA:US $ 40.99M 58.08M
Epizyme EPZM:US $ 77.42M 20.92M
Insmed INSM:US $ 515.7M 201.08M
Intercept Pharmaceuticals ICPT:US $ 48.32M 36.39M
Mirati Therapeutics MRTX:US $ 293.42M 100.32M
Omeros OMER:US $ 8.96M 91.84M
Orasure Technologies OSUR:US $ 70.72M 46.04M
Quidel QDEL:US $ 1275.54M 472.78M
Regulus Therapeutics RGLS:US $ 53.9M 6.48M
Revance Therapeutics RVNC:US $ 198.36M 87.74M
Ultragenyx Pharmaceutical RARE:US $ 153.99M 153.6M
United Therapeutics UTHR:US $ 813.3M 81.5M
Vital Therapies VTL:US $ 95.71M 8.85M